Cover Image
市場調查報告書

EpiCast Report:頭頸椎癌症的流行病學預測 (到2024年)

EpiCast Report: Head and Neck Cancers - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 353083
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:頭頸椎癌症的流行病學預測 (到2024年) EpiCast Report: Head and Neck Cancers - Epidemiology Forecast to 2024
出版日期: 2016年02月01日 內容資訊: 英文 80 Pages
簡介

所謂頭頸椎癌症 (HNC) ,包含各種口腔部相關癌症 (唇癌症、口腔癌症、咽癌症等) 和甲狀腺癌症,鼻腔、副鼻腔的相關癌症 (鼻子腫瘤,副鼻腔癌症等),喉癌症,甲狀腺癌症等寬廣的概念。NHC一般在頭部、頸部組織的粘膜表面由排成一列的鱗狀細胞發病。HNC在全球每個國家都經常發生,在主要7個國家的情況,接受診斷的發病者數,2014年為151,393人,預測2024年為174,056人和,以1.50%的年複合成長率 (CAGR) 增加。

本報告提供全球主要7個國家(美國、德國、法國、義大利、西班牙、英國、日本) 的頭頸椎癌症 (HNC) 及相關疾病的發病情形與今後預測相關分析,疾病的特徵,及目前患病者的發病情形,今後10年的患病數量的預測值等調查評估。

第1章 目錄

第2章 簡介

  • 疾病的概要
  • 相關分析
  • 出版預定的相關分析

第3章 流行病學

  • 疾病的背景情況
  • 風險要素和共生病症
  • 全世界的趨勢
    • 發病數量
    • 相對的存活率 (全球主要7個國家的情況)
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 頭頸椎癌症 (HNC)、甲狀腺癌症的流行病學的預測 (今後11年份)
    • 已受診的發病數量:唇癌症,口腔癌症,咽癌症
    • 已受診的發病數量:鼻子腫瘤,副鼻腔癌症,相關疾病
    • 已受診的發病數量:喉癌症
    • 已受診的發病數量:頭頸椎癌症 (HNC)
    • 已受診的發病數量:甲狀腺癌症
    • 各年齡的已受診發病者數:唇癌症,口腔癌症,咽癌症
    • 各年齡的已受診發病者數:喉癌症
    • 男女的已受診發病者數:甲狀腺癌症
    • 男女的已受診發病者數:唇癌症,口腔癌症,咽癌症
    • 男女的已受診發病者數:喉癌症
    • 男女的已受診發病者數:甲狀腺癌症
    • 已受診的發病數量 (年齡已調整):唇癌症,口腔癌症,咽癌症
    • 已受診的發病數量 (年齡已調整):喉癌症
    • 已受診的發病數量 (年齡已調整):甲狀腺癌症
    • 已受診的患病人數 (診斷時的各病期):喉癌症
    • 已受診的患病人數 (診斷時的各病期):唇癌症,口腔癌症,咽癌症
    • 已受診的患病人數 (診斷時的各病期):甲狀腺癌症
    • 已受診的患病人數 (診斷時的各病期):唇癌症,口腔癌症,咽癌症
    • 已受診的患病人數 (診斷時的各病期):鼻子腫瘤,副鼻腔癌症,相關疾病
    • 已受診的患病人數 (診斷時的各病期):喉癌症
    • 已受診的患病人數 (診斷時的各病期):甲狀腺癌症
    • 已受診的發病數量的預測 (今後5年份):唇癌症,口腔癌症,咽癌症
    • 已受診的發病數量的預測 (今後5年份):喉癌症
    • 已受診的發病數量的預測 (今後5年份):甲狀腺癌症
  • 討論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

目錄
Product Code: GDHCER115-16

Head and neck cancers (HNCs) are a heterogeneous group, consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth; the salivary glands; the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx; the nose, sinuses, and related structures; the larynx; and the thyroid. HNCs usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck - more than 80% of all HNCs are squamous cell carcinomas. HNCs are common in several regions across the globe and account for 600,000 new cases annually worldwide.

GlobalData epidemiologists forecast an increase in diagnosed incident cases of HNCs in the 7MM from 151,393 diagnosed incident cases in 2014 to 174,056 diagnosed incident cases in 2024, with an Annual Growth Rate (AGR) of 1.50% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of HNCs in the 7MM, with 65,663 diagnosed incident cases, whereas the UK will have the lowest number of diagnosed incident cases of HNCs, with 12,702 diagnosed incident cases in 2024. The diagnosed incident cases of thyroid cancer in the 7MM are expected to increase from 93,225 diagnosed incident cases in 2014 to 123,504 diagnosed incident cases in 2024, with an AGR of 3.25% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of thyroid cancer in the 7MM with 81,286 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of thyroid cancer with 3,233 diagnosed incident cases in 2024.

Scope

  • The Head and neck cancers (HNCs) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for HNCs in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases of HNCs segmented into three sub-groups: cancers of the lip, oral cavity, and pharynx; cancers of the nose, sinuses, and related structures; and cancers of the larynx, in these markets. It also includes a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of HNCs (excluding nose, sinuses, and related cancers). Additionally, it includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of thyroid cancer in the 7MM. The diagnosed incident cases of HNCs (excluding nose, sinuses, and related cancers) and thyroid cancer are segmented by age, sex, clinical stage at diagnosis, and histology.
  • The HNCs epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The HNCs EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HNCs market.
  • Quantify patient populations in the global HNCs market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HNCs therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. Incidence
    • 3.3.2. Relative Survival - 7MM
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for HNCs and Thyroid Cancer (2014-2024)
    • 3.5.1. Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
    • 3.5.2. Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers
    • 3.5.3. Diagnosed Incident Cases of Larynx Cancer
    • 3.5.4. Diagnosed Incident Cases of HNCs
    • 3.5.5. Diagnosed Incident Cases of Thyroid Cancer
    • 3.5.6. Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
    • 3.5.7. Age-Specific Diagnosed Incident Cases of Larynx Cancer
    • 3.5.8. Age-Specific Diagnosed Incident Cases of Thyroid Cancer
    • 3.5.9. Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
    • 3.5.10. Sex-Specific Diagnosed Incident Cases of Larynx Cancer
    • 3.5.11. Sex-Specific Diagnosed Incident Cases of Thyroid Cancer
    • 3.5.12. Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, and Pharynx Cancer
    • 3.5.13. Age-Standardized Diagnosed Incidence of Larynx Cancer
    • 3.5.14. Age-Standardized Diagnosed Incidence of Thyroid Cancer
    • 3.5.15. Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis
    • 3.5.16. Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis
    • 3.5.17. Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis
    • 3.5.18. Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution
    • 3.5.19. Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution
    • 3.5.20. Diagnosed Incident Cases of Larynx Cancer by Histology Distribution
    • 3.5.21. Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution
    • 3.5.22. Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer
    • 3.5.23. Five-Year Diagnosed Prevalent Cases of Larynx Cancer
    • 3.5.24. Five-Year Diagnosed Prevalent Cases of Thyroid Cancer
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: HNCs Clinical Stages at Diagnosis
  • Table 2: Risk Factors for HNCs
  • Table 3: Trends in the Age-Adjusted Incidence of Lip, Oral Cavity, and Pharynx Cancer in the 7MM, All Ages, 1998-2007
  • Table 4: Trends in the Age-Adjusted Incidence of Larynx Cancer in the 7MM, All Ages, 1998-2007
  • Table 5: Trends in the Age-Adjusted Incidence of Thyroid Cancer in the 7MM, All Ages, 1998-2007
  • Table 6: Trends in the Five-Year Relative Survival (%) of HNCs and Thyroid Cancer in the 7MM, Both Sexes, 1993-2007
  • Table 7: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
  • Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Larynx Cancer
  • Table 9: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer
  • Table 10: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Thyroid Cancer
  • Table 11: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer
  • Table 12: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Larynx Cancer
  • Table 13: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Thyroid Cancer
  • Table 14: 7MM, Sources of Epidemiological Data Used for the Segmentation of Diagnosed Incident Cases of HNCs (Excluding Nose, Sinuses, and Related Cancers) and Thyroid Cancer by Clinical Stage at Diagnosis
  • Table 15: 7MM, Sources of Epidemiological Data Used for the Segmentation of the Diagnosed Incident Cases HNCs and Thyroid Cancer by Histology Distribution
  • Table 16: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014-2024
  • Table 17: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014-2024
  • Table 18: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014-2024
  • Table 19: 7MM, Diagnosed Incident Cases of HNCs, Both Sexes, All Ages, N, 2014-2024
  • Table 20: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014-2024
  • Table 21: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N (Row %), 2014
  • Table 22: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N (Row %), 2014
  • Table 23: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N (Row %), 2014
  • Table 24: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N (Row %), 2014
  • Table 25: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N (Row %), 2014
  • Table 26: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N (Row %), 2014
  • Table 27: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014-2024
  • Table 28: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014-2024
  • Table 29: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014-2024

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014-2024
  • Figure 2: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014-2024
  • Figure 3: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014-2024
  • Figure 4: 7MM, Diagnosed Incident Cases of HNCs, Both Sexes, All Ages, N, 2014-2024
  • Figure 5: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014-2024
  • Figure 6: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N, 2014
  • Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N, 2014
  • Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N, 2014
  • Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N, 2014
  • Figure 10: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N, 2014
  • Figure 11: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N, 2014
  • Figure 12: 7MM, Age-Standardized Diagnosed Incidence Cases of Lip, Oral Cavity, and Pharynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014
  • Figure 13: 7MM, Age-Standardized Diagnosed Incidence Cases of Larynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014
  • Figure 14: 7MM, Age-Standardized Diagnosed Incidence Cases of Thyroid Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014
  • Figure 15: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014
  • Figure 16: 7MM, Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014
  • Figure 17: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014
  • Figure 18: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014
  • Figure 19: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution, All Ages, Both Sexes, N, 2014
  • Figure 20: 7MM, Diagnosed Incident Cases of Larynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014
  • Figure 21: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014
  • Figure 22: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 23: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 24: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014-2024
Back to Top